BioMedNewsBreaks – Applied UV Inc. (NASDAQ: AUVI) Enters Non-Binding LOI to Acquire Airocide(TM) System for Airborne Pathogen Reduction

Applied UV (NASDAQ: AUVI), an infection prevention technology company that applies the power of ultra violet C (“UV-C”) light utilizing its patented devices to destroy pathogens, today announced its entry into a non-binding letter of intent (“LOI”) with Akida Holdings LLC. In addition to its exclusive joint distribution and licensing agreement with Akida Holdings, the LOI is to explore the possibility of acquiring certain key assets of Akida. This includes Akida’s rights to the manufacture and sale of the Airocide(TM) System of patented, air purification technologies, which may aid in the reopening of the global economy with applications in the hospitality, hotel, healthcare, nursing homes, grocer, wine, commercial buildings and retail sectors.

To view the full press release, visit https://ibn.fm/6N770

About Applied UV Inc.

Applied UV is focused on the development and acquisition of technology that address infection prevention in the healthcare, hospitality, commercial and residential markets. The company’s products utilize disinfection technology that applies the power of UVC to destroy pathogens safely, thoroughly and automatically. Applied UV’s SteriLumen technology was tested at an independent laboratory that found the SteriLumen Disinfection System to be greater than 99.99% effective in killing the OC43 human coronavirus, a strain of human coronavirus that is genetically similar to SARS-CoV-2. According to the independent laboratory, it is expected that SARS-CoV-2, the virus that causes COVID-19, will be killed in a similar manner to OC43. The company has two wholly-owned subsidiaries: SteriLumen and Munn Works, LLC. SteriLumen develops disinfection devices and technology that combat hospital-acquired infections (“HAIs”). It has formed a team to solve and patent a product and process to neutralize pathogens providing a compelling solution for the hospitality space and a solid path to entering the healthcare market. Munn Works manufactures fine mirrors specifically for the hospitality industry. Its goal is to contribute to the creation of its design industry clients, manufacturing extraordinary framed mirrors. For more information about Applied UV Inc. and its subsidiaries, visit www.AppliedUVInc.com, www.SteriLumen.com and www.MunnWorks.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies…

8 hours ago

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB:…

8 hours ago

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic…

10 hours ago

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026…

10 hours ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of…

10 hours ago